肿瘤细胞来源的热休克蛋白70-肽复合物诱导的抗肿瘤疗效研究
Study on the anti-tumor efficacy induced by heat shock protein 70-peptide complexes derived from tumor cells.
作者信息
Fu Qingguo, Zhang Wei, Meng Fandong, Guo Renxuan, Yao Zhenyu
机构信息
The Second General Surgery Department, the First Affiliated Hospital of China Medical University, Shenyang 110001.
出版信息
Chin Med Sci J. 2002 Sep;17(3):153-6.
OBJECTIVE
To study the efficacy and explore the mechanism of the anti-tumor immunity elicited by heat shock protein 70-peptide complexes (HSP70-PC) derived from tumor cells.
METHODS
Cells culture, flow cytometric analysis, affinity chromatography for protein purification, SDS-PAGE, Western-blotting and animal experiment were used.
RESULTS
HSP70-PC immunization rendered protective effect to both naive tumorl-bearing mice. All of the naive mice obtained complete resistance to Hcaf cell attack; 40% of the tumor-bearing mice survived for over 90 days, whereas the mice of control group died within 2 weeks (P < 0.01). CD8+ subset of T lymphocytes in the peripheral blood of immunized mice increased by 12%.
CONCLUSION
HSP70-PC induces anti-tumor immunity via activation of cytotoxic T lymphocytes (CTLs), and it possesses strong tumor vaccine effect. Our research adds more evidence to support the clinical use of HSP70-PC to fight human cancers.
目的
研究肿瘤细胞来源的热休克蛋白70-肽复合物（HSP70-PC）引发的抗肿瘤免疫的疗效并探索其机制。
方法
采用细胞培养、流式细胞术分析、蛋白质纯化的亲和层析、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳、蛋白质免疫印迹法及动物实验。
结果
HSP70-PC免疫对未患肿瘤的荷瘤小鼠均有保护作用。所有未患肿瘤的小鼠对Hcaf细胞攻击获得完全抗性；40%的荷瘤小鼠存活超过90天，而对照组小鼠在2周内死亡（P<0.01）。免疫小鼠外周血中T淋巴细胞的CD8+亚群增加了12%。
结论
HSP70-PC通过激活细胞毒性T淋巴细胞（CTL）诱导抗肿瘤免疫，且具有强大的肿瘤疫苗效应。我们的研究为支持HSP70-PC用于对抗人类癌症的临床应用增添了更多证据。
Zotero 插件